Jenken Biosciences signed a services agreement valued at up to $2 million with Cato Research, a global CRO, and Cato BioVentures, its venture capital affiliate. Under Cato BioVentures' equity-based compensation model, Cato Research will provide strategic drug development services and regulatory advice related to the clinical development of JKB-122, Jenken's lead drug candidate for the treatment or prevention of liver damage associated with hepatitis C and other diseases associated with organ inflammation.
"Cato BioVentures and Cato Research are committed to working with early- stage companies like Jenken. When we partner early, as we have here, we can make a positive difference in the overall development of promising drug candidates like Jenken's JKB-122, a compound with exciting potential to impact the treatment of hepatitis C-related inflammatory liver disease," said Shawn K. Singh, managing principal of Cato BioVentures. "This strategic development agreement is flexible, broad-based and reflects a tight fit between our venture program and Jenken's innovative drug repurposing model."